Ignite Creation Date:
2024-05-06 @ 5:51 PM
Last Modification Date:
2024-10-26 @ 2:36 PM
Study NCT ID:
NCT05451043
Status:
RECRUITING
Last Update Posted:
2024-06-12
First Post:
2022-07-05
Brief Title:
Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors BLOCKED
Sponsor:
AHS Cancer Control Alberta
Organization:
AHS Cancer Control Alberta
Study Overview
Official Title:
A Study to Evaluate the Efficacy of Propranolol in Boosting Immunotherapy in Hepatocellular Carcinoma Cholangiocarcinoma and Pancreatic Adenocarcinoma
Status:
RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A single-arm interventional study combining Immunotherapy and propranolol withwithout chemotherapy and propranolol
1 Pancreatic Cancer Durvalumab will be administered once every 4 weeks in combination with gemcitabine nab-paclitaxel day 1815 and continuous propranolol Tremelimumab will be given on day 1 of cycle 1 which may be repeated at the time of progression in eligible patients
2 HCC Durvalumab will be administered once every 4 weeks in combination with continuous propranolol Tremelimumab will be given on day 1 of cycle 1 which may be repeated at the time of progression in eligible patients
3 Biliary Tract Cancer BTC Cholangiocarcinoma of the gallbladder or bile ducts Durvalumab will be administered once every 3 weeks in combination with cisplatin gemcitabine day 18 and continuous propranolol Tremelimumab will be given on day 1 of cycle 1 which may be repeated at the time of progression in eligible patients
1 Pancreatic Cancer Durvalumab will be administered once every 4 weeks in combination with gemcitabine nab-paclitaxel day 1815 and continuous propranolol Tremelimumab will be given on day 1 of cycle 1 which may be repeated at the time of progression in eligible patients
2 HCC Durvalumab will be administered once every 4 weeks in combination with continuous propranolol Tremelimumab will be given on day 1 of cycle 1 which may be repeated at the time of progression in eligible patients
3 Biliary Tract Cancer BTC Cholangiocarcinoma of the gallbladder or bile ducts Durvalumab will be administered once every 3 weeks in combination with cisplatin gemcitabine day 18 and continuous propranolol Tremelimumab will be given on day 1 of cycle 1 which may be repeated at the time of progression in eligible patients
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
False
Is an FDA AA801 Violation?:
None